Following FDA warning, Jubilant resolves quality issues

Jubilant Life Sciences has announced the successful resolution of issues raised by US FDA through warning letter for its Montreal facility


Jubilant Life Sciences has received a communication from the U.S. Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as ‘Acceptable'. The company announced the same on February 28, 2014. 

"This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications. The development follows completionof FDA's review of the Company's responses post the February letter and the subsequent re-inspection conducted at Jubilant's Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility,"mentioned the statement from the Jubilant. 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email